VANCOUVER, Sept. 26, 2011 /PRNewswire/ - iCo Therapeutics Inc. (TSXV: ICO) today announced that the company has entered into a research collaboration agreement with JDRF, the worldwide leader for research to cure, treat, and prevent type 1 diabetes (T1D),
PASADENA, Calif.--(BUSINESS WIRE)--Children and young adults with diabetes are more likely to have asthma which may affect their ability to manage their diabetes.
(Medical Xpress) -- Researchers at Washington University School of Medicine in St. Louis have identified the first genetic variant associated with severity of coronary artery disease in patients with type 2 diabetes.
Researchers have identified the first genetic variant associated with severity of coronary artery disease in patients with type 2 diabetes. Though this variant is not likely the cause of more severe coronary disease, the researchers say, it implicates a g
Researchers at Washington University School of Medicine in St. Louis have identified the first genetic variant associated with severity of coronary artery disease in patients with type 2 diabetes.